Project Grant K22CA282363
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$183K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $234,749 to The Ohio State University to conduct a Phase Ib clinical trial examining the effects of combining a hedgehog inhibitor (vismodegib) with an anti-PD-L1 immunotherapy (atezolizumab) in patients with metastatic non-small cell lung cancer. The goal is to understand how hedgehog signaling in tumor-associated macrophages within the tumor microenvironment suppresses CD8+...
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $540,288 Project Grant to the University of Florida to research the role of bacterial-derived small molecules in improving the efficacy of immunotherapy for non-small cell lung cancer (NSCLC). The project aims to characterize a bacterial metabolite called BAC429, which has been shown to augment the anti-tumor effects of anti-PD-1 immunotherapy in preclinical models. The research will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University totals $1,791,693 over a 5-year period from August 1, 2024 to July 31, 2029. The objectives of this research project are to investigate how blocking the CD200R immune checkpoint can enhance cancer immunotherapy by improving the recruitment and function of tumor-infiltrating immune cells, as well as inhibiting tumor angiogenesis. The research will evaluate the roles...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $563,233.00 to The Medical University of South Carolina (MUSC) to conduct research aimed at overcoming immunosuppression in the tumor microenvironment. The key goals of the project are to: Determine how the sphingosine kinase 2 (SPHK2)-mediated sphingosine-1-phosphate (S1P) signaling axis induces an immunosuppressive phenotype in myeloid-derived suppressor cells (MDSCs). Elucidate the...
The National Cancer Institute (NCI) awarded a $678,723 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Baylor College of Medicine to investigate the role of PD-L1 protein modifications in lung cancer diagnosis, prognosis, and treatment. The 5-year project, which began on February 21, 2025, aims to ascertain the pathobiological significance of non-proteolytic ubiquitination of PD-L1 and its impact on tumor cell evasion of T cell-mediated killing. Specifically, the project will evaluate...
The federal Project Grant award of $281,370 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at The Ohio State University to overcome immunotherapy resistance in lung cancers with STK11 gene mutations. The key objectives are to: 1) characterize the relationship between tumor differentiation phenotypes, the tumor immune microenvironment, and response to immune checkpoint blockade, including validating a novel STK11-MLDD biomarker; and 2)...
The National Cancer Institute (NCI) awarded a 3-year, $196,029 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Massachusetts Medical School (UMass Medical) to conduct research on understanding the immune evasion mechanisms in cancers driven by mutations in the IDH1 gene. The key objectives of the project are to: 1) Decipher the role of viral mimicry in the response to IDH1 inhibition, and 2) Explore the contribution of metabolic crosstalk to immune...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $684,367 to the Baylor College of Medicine to conduct research aimed at identifying new predictors of response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The key objectives are to: 1) Identify intratumoral microbiome profiles predictive of ICI response using whole-metagenome sequencing; 2) Characterize spatial immune...